AmpliPhi Biosciences Corporation and C3J Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J in an all-stock transaction, subject to shareholder approval. Mr. Todd R. Patrick of C3J will be the Chief Executive Officer of the combined company and Dr. Brian Varnum of C3J will be appointed President and Chief Development Officer. Steve Martin, AmpliPhi's Chief Financial Officer, will continue to act as the CFO of the combined company.

Dr. Grint has agreed to act as a clinical consultant for the combined company.